Introduction & Objective: to assess glucometabolic effects of OM, a novel fully digestible SDC.
Methods: In a cross-over RCT, we tested 33g and 50g of OM/MD in PwO (n=26, mean age 44 yrs, BMI 29.9 kg/m2, HbA1c 5.3%), and 50g in people with T2D (n=22, age 61 yrs, BMI 31.8 kg/m2, HbA1c 7.4%). OM/MD was dissolved in water (300mL) and consumed fasted. The primary exploratory endpoint was the incremental area under the curve (iAUC) for glucose, assessed by frequent blood sampling over 3h. Insulin and GLP-1 were also assessed. Analysis was performed by a mixed model (LS mean [95% CI]).
Results: OM elicited a significantly lower PP glucose response vs MD, for both doses in PwO (Fig) (e.g., 0-60 min 33g: ΔGlu iAUC -38% [-12.95 (-19.50, -6.41) mg/dLxh, p=0.0002]; 50g: -28% [-10.07 (-16.52, -3.61), p=0.0027]), as well as for PP insulin response (-60% to -38% across dose, and time periods, Fig [all p <0.05]). The 0-90 min PP GLP-1 response with OM relative to MD was smaller (50g: -24.2% [p=0.0425]; 33g: -22.7% [p=0.1883]), whereas 90-180 min larger (Fig; 50g: +408.6% [p<0.0001]; 33g: +308.0% [p=0.0036]. Patterns were similar in people with T2D.
Conclusion: The results underscore a slow hydrolysis of OM, and support it`s glucometabolic advantages over MD, hence representing a healthier carbohydrate.
O. Johansen: Employee; Nestlé Health Science. J.M. Neutel: None. S. Gupta: None. B. Mariani: None. G. Ufheil: Employee; Nestlé Health Science. E. Perrin: Other Relationship; Nestlé Health Science. N. Ocampo: None. M. von Eynatten: Employee; Nestlé Health Science.
